## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./ PTO/SB/08# (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Sue Xu Liu

100051.10171

Under the Paperiodic Reduction Act of 1985, no persons are required to record to a collection of information under the Commenter of the Commen

Examiner Name

Attorney Docket Number

(Use as many sheets as necessary)

of 2

Sheet 1

U.S. PATENT DOCUMENTS							
Examiner	Cito	Document Number	Publication/Issue Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Releva		
Initials *	Cite No.1	Number - Kind Code <sup>2</sup> (# known)	MM-DD-YYYY	Cited Socuriors	Passages or Relevant Figures Appear		
	1	US-5,962,220	10-05-1999	Waldman			
	2	US-5,518,888	05-21-1996	Waldman			
	3	US-4,411,888	10-25-1983	Klipstein et al.			
	4	US-4,867,973	09-19-1989	Goers et al.			
		US-					
		US-					
		US-					
		US-					
		US					
		US-					
		US-					
	T	US-					
		US-					
	1	US-					
	Г	U\$-					
		U\$-	,				
		110.					

Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>6</sup> (if known)	Date/Filing Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T°
	5	JP 63-501876 (w/Eng. abstract from corr. EP 0271180)	07-28-1998	Dow Chemical		
	6	JP 04-503945 (w/Eng. abstract from corr. WO 90/03801	07-16-1992	Univ of So. California		
	7	JP 06-503347 (w/Eng. abstract from corr. WO 92/11037)	04-14-1994	Advanced Magnetics		
	8	JP 06-511466 (w/Eng. abstract from corr. WO 93/02709)	12-22-1994	Microcarb		
	9	JP 04-503307 (w/Eng. abstract from corr. to WO 90/09197)	06-18-1992	Oncogen		
		WO 93/02708	02-18-1993	Antisoma		

Signature Considered 01/20/2010	Examiner Signature	/Sue Liu/	Date Considered	01/26/2010	
---------------------------------	-----------------------	-----------	--------------------	------------	--

"EXAMINER: Initial it reference considered, whether or not clation is in conformance with MPEP 609. Draw size through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's origine clatico designation number (optional). "See Kinds Codes of USPP 0 Amount of Communication in the Communication of Communication (optional)." See Kinds Codes of USPP 0 Amount of Communication number (optional). "See Kinds Codes of USPP 0 Amount of Codes o

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file und by the USPTO to process) an application. Confloratingly is governed by 58 U.S.C. 129 and 37 CFR 1.14. This collection is estimated to state 2 not complete, including againstring, preparing, and submitting the completed applications from to the USPTO. Then will vary depending upon the individual case, Any comments on the amount of time you require to complete is from marker supegesters for reducing this burrele, should be sent to the Cheff information Officer, U.S. Posteriment of Commerce, P.O. Box 1450, Alexandria, VA. 2231-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissions for Patients, P.O. Box 1450, Alexandria, VA. 2231-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissions for Patients, P.O. Box 1450, Alexandria, VA. 2231-1450.

## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute I	for form 1449B/PTC	)		Complete if Known		
		ь.	OL COURT	Application Number	10/621,684	
			CLOSURE	Filing Date	July 17, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Scott A. Waldman	
				Art Unit	1639	
	(Use as many she	ets as	necessary)	Examiner Name	Sue Xu Liu	
Sheet	2	of	2	Attorney Docket Number	100051.10171	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dviy and/or country where published.	T²
	10	Eildon "Cytotoxicity and viability assays," Animal Cell Culture: A Practical Approach, Freshney, R.I. (Ed.), IRL Press, Oxford, pages 183-216 (1986).	
	11	Drewett et al., "The family of guanylyl cyclase receptors and their ligands," Endocrine Reviews (1994) 15(2):135-162.	
	12	Waldman et al., "Influence of a glycine or proline substitution on the functional properties of a 14- amino-acid analog of Escherichia coli heat-stable enterotoxin," Infection and Immunity (1989) 57:2420-2424.	
	13	White et al., "Opossum kidney contains a functional receptor for the escherichia coli heat-stable enterotoxin," Biochemical and Biophysical Res Comm (1989) 159(1):363-357.	
	14	Shimonishi et al., "Mode of disulfide bond formation of a heat-stable enterotoxin (STn) produced by a human strain of enterotoxigenic Escherichia coll," Elsevier Science (1987) 215(1):165-170.	
		•	

Examiner Signature	/Sue Liu/	Date Considered	01/26/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

"Applicant's unique station designation number (optional)." Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CPR 1.98. The information is required to obtain or retain a benefit by the public which is to like (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Childriformation Officer, U.S. Patient and Trademark Office, U.S. Department of Commerce, P.O. Box 1469, Alexandric, VA 22313-1459, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.